| Literature DB >> 16709260 |
Bartosz Pilch1, Matthias Mann.
Abstract
BACKGROUND: The development of mass spectrometric (MS) techniques now allows the investigation of very complex protein mixtures ranging from subcellular structures to tissues. Body fluids are also popular targets of proteomic analysis because of their potential for biomarker discovery. Seminal plasma has not yet received much attention from the proteomics community but its characterization could provide a future reference for virtually all studies involving human sperm. The fluid is essential for the survival of spermatozoa and their successful journey through the female reproductive tract.Entities:
Mesh:
Substances:
Year: 2006 PMID: 16709260 PMCID: PMC1779515 DOI: 10.1186/gb-2006-7-5-r40
Source DB: PubMed Journal: Genome Biol ISSN: 1474-7596 Impact factor: 13.583
Figure 1An overview of the procedure used for identification of the seminal plasma proteome.
Figure 2Two consecutive stages of mass spectrometric fragmentation (MS3). (a) The precursor of a peptide LTPITYPQGLAMAK (see insert) was selected for fragmentation from a full scan of mass-to-charge ratio (m/z) range. (b) A fragment of the above, the doubly charged y12 ion, was subsequently fragmented. (c) The characteristic pattern for charged directed fragmentation is observed in MS3 spectra and confirms the identification of the above peptide.
Figure 3GoMiner analysis of the molecular function of identified proteins.
A list of identified inhibitors of serine proteases
| Accession number | Protein name | Molecular mass (Da) | Number of peptides |
| Q5SYA8 | CD109 | 162,530 | 28 |
| P01009 | Alpha-1-antitrypsin | 48,436 | 26 |
| P05154 | Plasma serine protease inhibitor | 45,787 | 19 |
| P29622 | Kallistatin | 50,808 | 15 |
| P05155 | Plasma protease C1 inhibitor | 57,067 | 13 |
| Q99574 | Neuroserpin | 46,397 | 13 |
| P35237 | Placental thrombin inhibitor | 42,904 | 13 |
| P03973 | Antileukoproteinase 1 | 15,228 | 12 |
| O43278 | Kunitz-type protease inhibitor 1 | 58,616 | 10 |
| Q8TF48 | Inter-alpha (Globulin) inhibitor H5 | 106,524 | 9 |
| O43692 | 25 kDa trypsin inhibitor | 59,557 | 9 |
| P30086 | Phosphatidylethanolamine-binding protein | 25,361 | 8 |
| P01019 | Angiotensinogen | 54,465 | 7 |
| Q06481-1 | Amyloid-like protein 2 | 87,927 | 6 |
| P01011 | Alpha-1-antichymotrypsin | 50,767 | 6 |
| P05067-1 | Amyloid beta A4 protein | 87,914 | 5 |
| P08697 | Alpha-2-antiplasmin | 56,917 | 5 |
| P23352 | Anosmin 1 | 77,444 | 4 |
| Q14508-1 | WAP four-disulfide core domain protein 2 | 13,953 | 4 |
| P20155 | Serine protease inhibitor Kazal-type 2 | 9,627 | 4 |
| P29508 | Squamous cell carcinoma antigen 1 | 44,594 | 3 |
| P49223 | Kunitz-type protease inhibitor 3 | 7,744 | 3 |
| P01008 | Antithrombin-III | 53,114 | 2 |
| P36955 | Pigment epithelium-derived factor | 48,809 | 2 |
| P08185 | Corticosteroid-binding globulin | 45,283 | 2 |
| Q8IUA0 | WAP four-disulfide core domain protein 8 | 29,489 | 2 |
| P05543 | Thyroxine-binding globulin | 46,637 | 1 |
| P36952 | Maspin | 42,568 | 1 |
| P02760 | AMBP protein | 39,886 | 1 |
| P48307 | Tissue factor pathway inhibitor 2 | 29,567 | 1 |
| Q9BQN3 | PREDICTED: similar to dJ601O1.1 (novel protein with Kunitz) | 15,847 | 1 |
Figure 4A comparison between proteins identified in the present study and two proteomics datasets published recently [10,11].